Purpose: To identify potential novel biomarkers and to explore new small-molecule drugs for heart failure (HF). Methods: The Gene Expression Omnibus (GEO) microarray datasets were downloaded for analyzing the differentially expressed genes (DEGs). Venn analysis was performed to calculate the overlapping genes which were then used for Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis using cluster Profiler in R package; a protein-protein interaction network (PPI) was constructed using STRING database. The hub genes were selected for small-molecule drug identification, while molecular docking of small-molecule drugs and hub genes was performed using CBdock2. Results: Upregulated and downregulated DEGs were obtained from GSE84796, GSE107569 and GSE116250 datasets, respectively. Eleven (11) overlapping genes, which were enriched in collagen fiber tissue, collagen-containing extracellular matrix and collagen fiber-related pathways, were also enriched in AGE-RAGE and relaxin signaling pathways. The PPI network of the DEGs was constructed, and five hub genes, with high connectivity, were significantly upregulated in HF. The five hub genes were ranked as MFAP4, LTBP2, THBS4, COL3A1 and COL1A1. Two targets (COL1A1 and COL3A1) matched potential drugs, and fostamatinib shared by the two targets had the greatest therapeutic value for HF. Conclusion: Five novel biomarkers and involved signaling pathways have been identified in HF via comprehensive microarray analyses. The results also show that fostamatinib might be a promising drug candidate for HF treatment
{"title":"Identification of potential biomarkers and candidate smallmolecule drugs for heart failure via comprehensive gene microarray analysis","authors":"Hailang Liu, Chunyang Yu, Zhongcheng Wei, Qing Zhang","doi":"10.4314/tjpr.v22i10.7","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.7","url":null,"abstract":"Purpose: To identify potential novel biomarkers and to explore new small-molecule drugs for heart failure (HF). Methods: The Gene Expression Omnibus (GEO) microarray datasets were downloaded for analyzing the differentially expressed genes (DEGs). Venn analysis was performed to calculate the overlapping genes which were then used for Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis using cluster Profiler in R package; a protein-protein interaction network (PPI) was constructed using STRING database. The hub genes were selected for small-molecule drug identification, while molecular docking of small-molecule drugs and hub genes was performed using CBdock2. Results: Upregulated and downregulated DEGs were obtained from GSE84796, GSE107569 and GSE116250 datasets, respectively. Eleven (11) overlapping genes, which were enriched in collagen fiber tissue, collagen-containing extracellular matrix and collagen fiber-related pathways, were also enriched in AGE-RAGE and relaxin signaling pathways. The PPI network of the DEGs was constructed, and five hub genes, with high connectivity, were significantly upregulated in HF. The five hub genes were ranked as MFAP4, LTBP2, THBS4, COL3A1 and COL1A1. Two targets (COL1A1 and COL3A1) matched potential drugs, and fostamatinib shared by the two targets had the greatest therapeutic value for HF. Conclusion: Five novel biomarkers and involved signaling pathways have been identified in HF via comprehensive microarray analyses. The results also show that fostamatinib might be a promising drug candidate for HF treatment","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"90 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guozhi Zhang, Lina Zhou, Shanshan Guo, Mei Wang, Ling Han
Purpose: To investigate the therapeutic benefits of terbutaline sulfate aerosol inhalation combined with budesonide, and its influence on pulmonary function in pregnant women suffering from acute bronchial asthma attacks.
Methods: A total of 100 pregnant patients diagnosed with acute bronchial asthma in PLA Strategic Support Force Characteristic Medical Center, Beijing, China were divided into control and study groups (n = 50 each). Control group received aerosol inhalation of normal saline along with standard treatments, viz, oxygen inhalation, sputum aspiration, anti-infection measures, and maintenance of water- electrolyte balance. Study group received combined terbutaline sulfate and budesonide aerosol inhalation in addition to standard treatment. Both groups underwent a 7-day treatment course, with inhalation therapy twice daily.
Results: Study group showed significantly shorter relief times for cough, wheezing, and chest tightness compared to control group (p < 0.05). After treatment, 92.0 % of patients in study group exhibited improvement or relief from their symptoms, compared to 80.0 % in control group (p < 0.05). Pulmonary function indices, including first vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), and FEV1/FVC, improved in both groups after treatment. Study group exhibited significantly lower laboratory indices, including immunoglobulin E (IgE), C-reactive protein (CRP), and eosinophils (EOS) compared to control group (p < 0.05).
Conclusion: The combination of inhalation therapy of terbutaline sulfate with budesonide in pregnant women experiencing acute bronchial asthma demonstrates significant enhancements in clinical effectiveness, pulmonary function, and laboratory parameters. Clinical trials of this combined therapy should be carried out in other locations to ascertain the effect of population variation on treatment efficacy.
{"title":"Effectiveness of the combination of terbutaline and budesonide inhalation in treating acute bronchial asthma during pregnancy","authors":"Guozhi Zhang, Lina Zhou, Shanshan Guo, Mei Wang, Ling Han","doi":"10.4314/tjpr.v22i10.26","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.26","url":null,"abstract":"Purpose: To investigate the therapeutic benefits of terbutaline sulfate aerosol inhalation combined with budesonide, and its influence on pulmonary function in pregnant women suffering from acute bronchial asthma attacks.
 Methods: A total of 100 pregnant patients diagnosed with acute bronchial asthma in PLA Strategic Support Force Characteristic Medical Center, Beijing, China were divided into control and study groups (n = 50 each). Control group received aerosol inhalation of normal saline along with standard treatments, viz, oxygen inhalation, sputum aspiration, anti-infection measures, and maintenance of water- electrolyte balance. Study group received combined terbutaline sulfate and budesonide aerosol inhalation in addition to standard treatment. Both groups underwent a 7-day treatment course, with inhalation therapy twice daily.
 Results: Study group showed significantly shorter relief times for cough, wheezing, and chest tightness compared to control group (p < 0.05). After treatment, 92.0 % of patients in study group exhibited improvement or relief from their symptoms, compared to 80.0 % in control group (p < 0.05). Pulmonary function indices, including first vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), and FEV1/FVC, improved in both groups after treatment. Study group exhibited significantly lower laboratory indices, including immunoglobulin E (IgE), C-reactive protein (CRP), and eosinophils (EOS) compared to control group (p < 0.05).
 Conclusion: The combination of inhalation therapy of terbutaline sulfate with budesonide in pregnant women experiencing acute bronchial asthma demonstrates significant enhancements in clinical effectiveness, pulmonary function, and laboratory parameters. Clinical trials of this combined therapy should be carried out in other locations to ascertain the effect of population variation on treatment efficacy.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"89 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the effect of 20-hydroxyecdysone (20E) and its metabolites and their synergistic effect with IGF-1 on regulation of skeletal muscle cell growth.
Methods: Mouse skeletal muscle cell line (C2C12) was solely treated with 20E and its metabolites (14- deoxy- 20-hydroxyecdysone, poststerone, and 14-deoxypoststerone) at doses of 0.1, 1, and 10 µM or co-treated with IGF-1 (10 ng/ml). Cell viability and proliferative capacity were evaluated using MTT and BrdU incorporation assays, respectively. Myogenic differentiation proteins [embryonic myosin heavy chain (EbMHC) and MHC], androgen receptor (AR), and IGF-1 receptor (IGF-1R) protein expression were investigated using immunocytochemistry.
Results: Treatments of 20E and its metabolites had no toxicity on skeletal muscle cells or induced AR/IGF-1R expression. In addition, solely treatment of 20E and its metabolites or co-treatment with IGF-1 had no significant effect on cell proliferation and myogenic differentiation capacity. In contrast, IGF-1 treatment alone significantly increased EbMHC expression (p<0.0001), MHC expression (p<0.05), and myotube number (p<0.05).
Conclusion: These results indicate that 20E and its metabolites have no direct or synergistic effect with IGF-1 on skeletal muscle cell growth. Nevertheless, the pharmacological effects of 20E on skeletal muscle mass and strength in vivo that raises its therapeutic potential may associate with its indirect action.
{"title":"Effect of 20-hydroxyecdysone and its metabolites in the absence or presence of IGF-1 on regulation of skeletal muscle cell growth","authors":"Kanokwan Suhatcho, Boon-ek Yingyongnarongkul, Saowanee Kumpun, Ratchakrit Srikuea","doi":"10.4314/tjpr.v22i10.11","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.11","url":null,"abstract":"Purpose: To investigate the effect of 20-hydroxyecdysone (20E) and its metabolites and their synergistic effect with IGF-1 on regulation of skeletal muscle cell growth.
 Methods: Mouse skeletal muscle cell line (C2C12) was solely treated with 20E and its metabolites (14- deoxy- 20-hydroxyecdysone, poststerone, and 14-deoxypoststerone) at doses of 0.1, 1, and 10 µM or co-treated with IGF-1 (10 ng/ml). Cell viability and proliferative capacity were evaluated using MTT and BrdU incorporation assays, respectively. Myogenic differentiation proteins [embryonic myosin heavy chain (EbMHC) and MHC], androgen receptor (AR), and IGF-1 receptor (IGF-1R) protein expression were investigated using immunocytochemistry.
 Results: Treatments of 20E and its metabolites had no toxicity on skeletal muscle cells or induced AR/IGF-1R expression. In addition, solely treatment of 20E and its metabolites or co-treatment with IGF-1 had no significant effect on cell proliferation and myogenic differentiation capacity. In contrast, IGF-1 treatment alone significantly increased EbMHC expression (p<0.0001), MHC expression (p<0.05), and myotube number (p<0.05).
 Conclusion: These results indicate that 20E and its metabolites have no direct or synergistic effect with IGF-1 on skeletal muscle cell growth. Nevertheless, the pharmacological effects of 20E on skeletal muscle mass and strength in vivo that raises its therapeutic potential may associate with its indirect action.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"89 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To study the influence of O3 exposure on cough sensitivity, airway barrier function and airway inflammation in mice.
Methods: Cough sensitivity was determined in healthy male C57/BL6 mice (aged 8 - 10 weeks) which were exposed to different concentrations of O3 (0.5 - 2 ppm) for 3 h daily for 9 days. Hematoxylin and eosin (H&E) staining of lung tissues, collection of BALF, and cell count were carried out. Inflammatory factor levels in pulmonary tissues were determined by enzyme-linked immunosorbent assay (ELISA), while Western blotting was used to assay TRPA1 and Claudin-1 protein expressions in lung tissues.
Results: After 9 days of mice exposure to O3, cough sensitivity increased significantly, and TRPA1 protein was increased in pulmonary tissues, with exposure level of 1 ppm resulting in the highest level of TRPA1 protein expression. Claudin-1 expression in lung tissues of mice decreased after O3 exposure, especially in the groups exposed to O3 levels of 0.5 ppm and 2 ppm. The total cell count in alveolar lavage fluid of mice exposed to O3 was significantly increased (p < 0.05). In addition, O3 exposure increased IL-1α, IL-6 and TNF-α levels, with the most significant increase in the 0.5 ppm group (p < 0.05). Results from histology revealed that all mice had inflammatory reactions and destruction of lung tissues after O3 exposure.
Conclusion: Exposure to O3 induces disruption of airway barrier function, infiltration of the airway by inflammatory cells, and increased secretion of inflammatory factors, thereby resulting in enhanced cough sensitivity.
{"title":"Ozone exposure induces cough hypersensitivity in mice","authors":"Tinglei Li, Shu Zhang, Xuemei Liu, Tianyuan Xin, Yu Chen, Zhe Chen","doi":"10.4314/tjpr.v22i10.14","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.14","url":null,"abstract":"Purpose: To study the influence of O3 exposure on cough sensitivity, airway barrier function and airway inflammation in mice.
 Methods: Cough sensitivity was determined in healthy male C57/BL6 mice (aged 8 - 10 weeks) which were exposed to different concentrations of O3 (0.5 - 2 ppm) for 3 h daily for 9 days. Hematoxylin and eosin (H&E) staining of lung tissues, collection of BALF, and cell count were carried out. Inflammatory factor levels in pulmonary tissues were determined by enzyme-linked immunosorbent assay (ELISA), while Western blotting was used to assay TRPA1 and Claudin-1 protein expressions in lung tissues.
 Results: After 9 days of mice exposure to O3, cough sensitivity increased significantly, and TRPA1 protein was increased in pulmonary tissues, with exposure level of 1 ppm resulting in the highest level of TRPA1 protein expression. Claudin-1 expression in lung tissues of mice decreased after O3 exposure, especially in the groups exposed to O3 levels of 0.5 ppm and 2 ppm. The total cell count in alveolar lavage fluid of mice exposed to O3 was significantly increased (p < 0.05). In addition, O3 exposure increased IL-1α, IL-6 and TNF-α levels, with the most significant increase in the 0.5 ppm group (p < 0.05). Results from histology revealed that all mice had inflammatory reactions and destruction of lung tissues after O3 exposure.
 Conclusion: Exposure to O3 induces disruption of airway barrier function, infiltration of the airway by inflammatory cells, and increased secretion of inflammatory factors, thereby resulting in enhanced cough sensitivity.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"91 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the effect of the co-administration of phentolamine and milrinone on severe pneumonia in children, as well as on serum MMP-9, TIMP-1 and sICAM-1 levels.
Methods: From January 2021 to January 2022, 100 patients diagnosed with severe pneumonia were randomly divided into 2 groups; the control group received oxygen inhalation and other symptomatic treatment, while the study group received phentolamine concurrently with milrinone, Serum MMP-9, TIMP-1, sICAM-1 levels and clinical efficacy were determined in the two groups before and after treatment.
Results: After treatment, there were significant differences in IL-6, IL-10, and TNF-α levels between the study group and the control group. Furthermore, IgA, IgG, and IgM levels in both groups were significantly higher after treatment than before treatment (p < 0.05). The study group exhibited significant differences in MMP-9, TIMP-1, and sICAM-1 levels after treatment compared to control group (p < 0.05). Healing and therapeutic effectiveness in the study group was 76 %, which was significantly greater than in the control group (48 %; p = 0.000). Additionally, total treatment effectiveness in the study group was 92 %, which was significantly higher than in the control group (80 %; p = 0.015). After treatment, the PEF, FRC, and TEF25 % in the study group were significantly higher than in the control group (p < 0.05).
Conclusion: Co-administration of phentolamine and milrinone is highly effective for the treatment of severe pneumonia in children, and significantly reduces the levels of serum MMP-9, TIMP-1 and sICAM-1. However, multi-center clinical trials should be carried out prior to the adoption of this treatment mode in clinical practice.
{"title":"Efficacy of phentolamine combined with milrinone on severe pneumonia in children, and its effect on serum levels of MMP-9, TIMP-1 and sICAM-1","authors":"Jianbiao Chen, Hualong Lv, Zhimian Liang","doi":"10.4314/tjpr.v22i10.16","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.16","url":null,"abstract":"Purpose: To investigate the effect of the co-administration of phentolamine and milrinone on severe pneumonia in children, as well as on serum MMP-9, TIMP-1 and sICAM-1 levels.
 Methods: From January 2021 to January 2022, 100 patients diagnosed with severe pneumonia were randomly divided into 2 groups; the control group received oxygen inhalation and other symptomatic treatment, while the study group received phentolamine concurrently with milrinone, Serum MMP-9, TIMP-1, sICAM-1 levels and clinical efficacy were determined in the two groups before and after treatment.
 Results: After treatment, there were significant differences in IL-6, IL-10, and TNF-α levels between the study group and the control group. Furthermore, IgA, IgG, and IgM levels in both groups were significantly higher after treatment than before treatment (p < 0.05). The study group exhibited significant differences in MMP-9, TIMP-1, and sICAM-1 levels after treatment compared to control group (p < 0.05). Healing and therapeutic effectiveness in the study group was 76 %, which was significantly greater than in the control group (48 %; p = 0.000). Additionally, total treatment effectiveness in the study group was 92 %, which was significantly higher than in the control group (80 %; p = 0.015). After treatment, the PEF, FRC, and TEF25 % in the study group were significantly higher than in the control group (p < 0.05).
 Conclusion: Co-administration of phentolamine and milrinone is highly effective for the treatment of severe pneumonia in children, and significantly reduces the levels of serum MMP-9, TIMP-1 and sICAM-1. However, multi-center clinical trials should be carried out prior to the adoption of this treatment mode in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"91 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the clinical efficacy of the combination of minocycline and periodontal basic treatment on type 2 diabetes mellitus (T2DM) patients with chronic periodontitis (CP) and its impact on inflammatory factors.
Methods: A total of 90 T2DM patients with CP admitted to the Department of Stomatology in Hainan Medical College Second Affiliated Hospital, China from January 2020 to October 2022, were enrolled in this study and randomly assigned to two equal groups, viz, study and control group. Study group received minocycline in addition to routine hypoglycemic control and basic periodontal treatment, while control group received only routine hypoglycemic control and basic periodontal treatment. Treatment lasted for 8 weeks. Efficacy of the combination of minocycline and periodontal basic treatment of T2DM patients with CP in the two groups, as well as the periodontal probing depth (PD), clinical attachment loss (CAL), bleeding on probing (sulcus bleeding index, SBI), interleukin-36 (IL-36), interleukin-1β (IL1β), tumor necrosis factor-α (TNF-α), glycated hemoglobin (HbA1c) level, chewing function score, Oral Health Impact Profile-14 (OHIP-14) score, and incidence of adverse reactions before and after treatment were determined.
Results: The effectiveness/efficacy of treatment in study group (91.11 %) was significantly higher than in control group (75.56 %, p < 0.05). After treatment, study group had reduced PD, PLI, and SBI scores than control group (p < 0.05). Study group also showed lower levels of IL-1β, IL-36, and TNF-α as well as reduced OHIP-14 score and a higher chewing function score than control group (p < 0.05).
Conclusion: The combination of minocycline with periodontal basic treatment improves the efficacy in T2DM patients with CP, and reduces the level of inflammatory factors with a good margin of safety.
{"title":"Efficacy of the combination of minocycline and periodontal basic therapy in type 2 diabetes mellitus patients with chronic periodontitis","authors":"Chuizhuang Chen, Shaodeng Li, Fuwen Xing","doi":"10.4314/tjpr.v22i10.17","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.17","url":null,"abstract":"Purpose: To investigate the clinical efficacy of the combination of minocycline and periodontal basic treatment on type 2 diabetes mellitus (T2DM) patients with chronic periodontitis (CP) and its impact on inflammatory factors.
 Methods: A total of 90 T2DM patients with CP admitted to the Department of Stomatology in Hainan Medical College Second Affiliated Hospital, China from January 2020 to October 2022, were enrolled in this study and randomly assigned to two equal groups, viz, study and control group. Study group received minocycline in addition to routine hypoglycemic control and basic periodontal treatment, while control group received only routine hypoglycemic control and basic periodontal treatment. Treatment lasted for 8 weeks. Efficacy of the combination of minocycline and periodontal basic treatment of T2DM patients with CP in the two groups, as well as the periodontal probing depth (PD), clinical attachment loss (CAL), bleeding on probing (sulcus bleeding index, SBI), interleukin-36 (IL-36), interleukin-1β (IL1β), tumor necrosis factor-α (TNF-α), glycated hemoglobin (HbA1c) level, chewing function score, Oral Health Impact Profile-14 (OHIP-14) score, and incidence of adverse reactions before and after treatment were determined.
 Results: The effectiveness/efficacy of treatment in study group (91.11 %) was significantly higher than in control group (75.56 %, p < 0.05). After treatment, study group had reduced PD, PLI, and SBI scores than control group (p < 0.05). Study group also showed lower levels of IL-1β, IL-36, and TNF-α as well as reduced OHIP-14 score and a higher chewing function score than control group (p < 0.05).
 Conclusion: The combination of minocycline with periodontal basic treatment improves the efficacy in T2DM patients with CP, and reduces the level of inflammatory factors with a good margin of safety.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"89 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lei Han, Jing Wang, Yu Xia, Jinping Maio, Juan Cao
Purpose: To determine the influence of oxaliplatin on skin squamous cell carcinoma cell line, and the involvement of autophagy- regulating pathway of high mobility group box 1 (HMGB1) in the process.
Methods: A431 cells cultured in vitro were used. The cells were divided into groups A (treated with different concentrations of oxaliplatin) and B (treated with different concentrations of oxaliplatin combined with autophagy inhibitor 5 mmol/l3-ma). Changes in expression levels of autophagy marker molecules LC3-Ⅰ, LC3-Ⅱ, p62 and HMGB1 in A431 cells treated with different concentrations of oxaliplatin and different concentrations of HMGB1 were evaluated by Western blotting. Viability of A431 cells in both groups was assessed by CCK-8 assay.
Results: With increase in oxaliplatin concentration, LC3-Ⅱ levels in A431 cells were up-regulated, p62 expression decreased, while autophagy level was increased significantly (p < 0.05). With increase in HMGB1 protein concentration, LC3-Ⅱ level in A431 cells was raised, while p62 level was reduced, while the level of autophagy was significantly increased (p < 0.05). Oxaliplatin treatment led to significantly higher expression level of HMGB1 in the experimental group than in the control group without oxaliplatin treatment. The viability of oxaliplatin-treated group was dose-dependently and significantly lower (p < 0.05) than that of the control group. Compared with the control group, the cell viability of the 3-mA + oxaliplatin group also showed a downward trend, and the decrease was greater than that of oxaliplatin-treated group (p < 0.05).
Conclusion: Oxaliplatin upregulates autophagy by promoting HMGB1 protein expression, which may be a protective mechanism of tumor cells against oxaliplatin cytotoxicity thereby making HMGB1 protein a potential target in skin cancer therapy.
{"title":"Oxaliplatin regulates the autophagy of skin squamous cell carcinoma cell line through HMGB1 pathway","authors":"Lei Han, Jing Wang, Yu Xia, Jinping Maio, Juan Cao","doi":"10.4314/tjpr.v22i10.5","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.5","url":null,"abstract":"Purpose: To determine the influence of oxaliplatin on skin squamous cell carcinoma cell line, and the involvement of autophagy- regulating pathway of high mobility group box 1 (HMGB1) in the process.
 Methods: A431 cells cultured in vitro were used. The cells were divided into groups A (treated with different concentrations of oxaliplatin) and B (treated with different concentrations of oxaliplatin combined with autophagy inhibitor 5 mmol/l3-ma). Changes in expression levels of autophagy marker molecules LC3-Ⅰ, LC3-Ⅱ, p62 and HMGB1 in A431 cells treated with different concentrations of oxaliplatin and different concentrations of HMGB1 were evaluated by Western blotting. Viability of A431 cells in both groups was assessed by CCK-8 assay.
 Results: With increase in oxaliplatin concentration, LC3-Ⅱ levels in A431 cells were up-regulated, p62 expression decreased, while autophagy level was increased significantly (p < 0.05). With increase in HMGB1 protein concentration, LC3-Ⅱ level in A431 cells was raised, while p62 level was reduced, while the level of autophagy was significantly increased (p < 0.05). Oxaliplatin treatment led to significantly higher expression level of HMGB1 in the experimental group than in the control group without oxaliplatin treatment. The viability of oxaliplatin-treated group was dose-dependently and significantly lower (p < 0.05) than that of the control group. Compared with the control group, the cell viability of the 3-mA + oxaliplatin group also showed a downward trend, and the decrease was greater than that of oxaliplatin-treated group (p < 0.05).
 Conclusion: Oxaliplatin upregulates autophagy by promoting HMGB1 protein expression, which may be a protective mechanism of tumor cells against oxaliplatin cytotoxicity thereby making HMGB1 protein a potential target in skin cancer therapy.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"91 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the efficacy and safety of 3 % diquafosol sodium combined with M22 optimized pulse light (OPT) in the treatment of dry eye due to meibomian gland dysfunction (MGD).
Methods: Data from 97 dry eye patients admitted to Shantou Balder Eye Hospital with MGD-induced dry eye illness between August 2019 and June 2021 were retrospectively reviewed and analyzed. Patients meeting MGD diagnostic criteria in ophthalmology and exhibiting MGD-induced dry eye signs were split into two groups. The medication group (43 cases) received 3 % diquafosol sodium eye drops six times a day for three months, while the pulsed light group (44 cases) underwent three M22 OPT sessions at one-month intervals. Treatment efficacy of the two methods were compared by assessing changes in ocular surface, symptom severity, inflammatory factors (hs-CRP, IL-8, IL-1β), and quality of life before and three months after treatment commenced. Adverse reactions were also recorded.
Results: Pulsed light group showed a slightly higher (but not significant) total effective rate (95.45 %) than the medication group (93.02 %; p > 0.05). Three months post-treatment, both groups exhibited significant improvements in various indicators such as FL, OSDI, symptom scores, tear biomarker levels, and overall eye health (p < 0.05). The incidence of adverse reactions was similar between the medication (4.65 %) and pulsed light (9.09 %) groups.
Conclusion: Treatment with 3 % diquafosol sodium and M22 OPT for MGD-induced dry eye yields comparable efficacy and safety, improving symptoms, ocular surface function, reducing inflammation, and enhancing quality of life. However, 3 % diquafosol sodium shows better patient tolerance and fewer adverse reactions, but further research is needed due to the limited number of patients in this study.
{"title":"Efficacy of diquafosol sodium combined with M22 optimized pulsed light in the treatment of dry eye due to meibomian gland dysfunction","authors":"Xiaodan Huang, Degui Wang, Dusheng Lin, Zhaotao Zhou","doi":"10.4314/tjpr.v22i10.18","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.18","url":null,"abstract":"Purpose: To determine the efficacy and safety of 3 % diquafosol sodium combined with M22 optimized pulse light (OPT) in the treatment of dry eye due to meibomian gland dysfunction (MGD).
 Methods: Data from 97 dry eye patients admitted to Shantou Balder Eye Hospital with MGD-induced dry eye illness between August 2019 and June 2021 were retrospectively reviewed and analyzed. Patients meeting MGD diagnostic criteria in ophthalmology and exhibiting MGD-induced dry eye signs were split into two groups. The medication group (43 cases) received 3 % diquafosol sodium eye drops six times a day for three months, while the pulsed light group (44 cases) underwent three M22 OPT sessions at one-month intervals. Treatment efficacy of the two methods were compared by assessing changes in ocular surface, symptom severity, inflammatory factors (hs-CRP, IL-8, IL-1β), and quality of life before and three months after treatment commenced. Adverse reactions were also recorded.
 Results: Pulsed light group showed a slightly higher (but not significant) total effective rate (95.45 %) than the medication group (93.02 %; p > 0.05). Three months post-treatment, both groups exhibited significant improvements in various indicators such as FL, OSDI, symptom scores, tear biomarker levels, and overall eye health (p < 0.05). The incidence of adverse reactions was similar between the medication (4.65 %) and pulsed light (9.09 %) groups.
 Conclusion: Treatment with 3 % diquafosol sodium and M22 OPT for MGD-induced dry eye yields comparable efficacy and safety, improving symptoms, ocular surface function, reducing inflammation, and enhancing quality of life. However, 3 % diquafosol sodium shows better patient tolerance and fewer adverse reactions, but further research is needed due to the limited number of patients in this study.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"89 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the suitability of sesame oil as an oily phase for diclofenac emulgel formulation.
Methods: Different batches of emulgel comprising different proportions of oils (sesame oil and/or Labrafac CC), surfactants (Tween-80 and/or cremophor EL-30), and gelling agents (xanthan gum or gelatin) were prepared. The formulations were evaluated for rheology, syneresis, Fourier transform infrared (FTIR) spectroscopy, spreadability, extrudability, and anti-inflammatory activity.
Results: Product characteristics of batches A2, A4, and A6 were not consistent with those of emulgels. Because Batch A1 showed characteristics that were the most stable, such as no pH changes, nonstatistically significant changes (p = 1.000) in the viscosity results, and least spectrum changes following FTIR investigation, it was selected as the best batch. It showed similar anti-inflammatory activity when compared with commercially available diclofenac emulgel, giving a 50 % higher anti-inflammatory effect than aqueous diclofenac dispersion.
Conclusion: Sesame oil is a potential lipophilic component in emulgel formulations for topical delivery of hydrophobic drugs.
{"title":"Evaluation of diclofenac emulgel prepared with sesame oil as a lipophilic carrier","authors":"Zwanden Sule Yahaya, Latifat Oyiza Otaru, Boma Blessing Mohammed, Olutayo Ademola Adeleye, Na'anman Charles Dagogot, Idris Abdullahi","doi":"10.4314/tjpr.v22i10.1","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.1","url":null,"abstract":"Purpose: To investigate the suitability of sesame oil as an oily phase for diclofenac emulgel formulation.
 Methods: Different batches of emulgel comprising different proportions of oils (sesame oil and/or Labrafac CC), surfactants (Tween-80 and/or cremophor EL-30), and gelling agents (xanthan gum or gelatin) were prepared. The formulations were evaluated for rheology, syneresis, Fourier transform infrared (FTIR) spectroscopy, spreadability, extrudability, and anti-inflammatory activity.
 Results: Product characteristics of batches A2, A4, and A6 were not consistent with those of emulgels. Because Batch A1 showed characteristics that were the most stable, such as no pH changes, nonstatistically significant changes (p = 1.000) in the viscosity results, and least spectrum changes following FTIR investigation, it was selected as the best batch. It showed similar anti-inflammatory activity when compared with commercially available diclofenac emulgel, giving a 50 % higher anti-inflammatory effect than aqueous diclofenac dispersion. 
 Conclusion: Sesame oil is a potential lipophilic component in emulgel formulations for topical delivery of hydrophobic drugs.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"88 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the effect of different doses of dexmedetomidine on the quality of postoperative recovery, incidence of postoperative delirium, and cognitive function in elderly patients undergoing lower limb surgery.
Methods: A total of 112 patients who received treatment in the Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, Hothot, China from January 2021 to January 2023 were divided into 3 groups, consisting of low-dose group (35 patients received 0.2 mg/kg), medium-dose group (39 patients received 0.4 mg/kg), and high-dose group (38 patients received 0.6 mg/kg). Parameters including, convalescence quality of general anesthesia, incidence of postoperative delirium, adverse reactions, Mini- mental State Examination (MMSE) scores, sedation effect (Ramsay), analgesia effect (visual analogue scale (VAS)), and stress indices, viz, norepinephrine (NE), epinephrine (E), and cortisol (COR) levels), were evaluated and compared.
Results: There was no significant difference in tracheal extubation time, recovery time of spontaneous breathing, calling eye-opening time, or full awakening time among the three groups (p > 0.05). However, MMSE score was significantly higher in low-dose group on days 1 and 3 after surgery (p < 0.05) and VAS scores were significantly higher in low-dose group at 12 and 24 h after recovery compared to other groups (p < 0.05). Ramsay score was significantly higher in high-dose group (p < 0.05). Levels of NE, E, and COR were significantly lower in medium-dose group compared to other groups (p < 0.05). Incidence of adverse reactions were significantly lower in low and medium-dose groups compared to high- dose group (p < 0.05).
Conclusion: Medium-dose dexmedetomidine demonstrates favorable sedative and analgesic effects with minimal impact on cognitive function and stress response in elderly patients undergoing lower limb surgery. Furthermore, it does not affect quality of postoperative recovery nor incidence of postoperative delirium. More large-scale, randomized controlled studies are needed to confirm these results.
{"title":"Effect of dexmedetomidine on convalescence quality after general anesthesia and postoperative delirium, and on cognitive function in elderly patients undergoing lower limb surgery","authors":"Wenbo Wei, Lele Guo","doi":"10.4314/tjpr.v22i10.22","DOIUrl":"https://doi.org/10.4314/tjpr.v22i10.22","url":null,"abstract":"Purpose: To investigate the effect of different doses of dexmedetomidine on the quality of postoperative recovery, incidence of postoperative delirium, and cognitive function in elderly patients undergoing lower limb surgery.
 Methods: A total of 112 patients who received treatment in the Department of Anesthesiology, Affiliated Hospital of Inner Mongolia Medical University, Hothot, China from January 2021 to January 2023 were divided into 3 groups, consisting of low-dose group (35 patients received 0.2 mg/kg), medium-dose group (39 patients received 0.4 mg/kg), and high-dose group (38 patients received 0.6 mg/kg). Parameters including, convalescence quality of general anesthesia, incidence of postoperative delirium, adverse reactions, Mini- mental State Examination (MMSE) scores, sedation effect (Ramsay), analgesia effect (visual analogue scale (VAS)), and stress indices, viz, norepinephrine (NE), epinephrine (E), and cortisol (COR) levels), were evaluated and compared.
 Results: There was no significant difference in tracheal extubation time, recovery time of spontaneous breathing, calling eye-opening time, or full awakening time among the three groups (p > 0.05). However, MMSE score was significantly higher in low-dose group on days 1 and 3 after surgery (p < 0.05) and VAS scores were significantly higher in low-dose group at 12 and 24 h after recovery compared to other groups (p < 0.05). Ramsay score was significantly higher in high-dose group (p < 0.05). Levels of NE, E, and COR were significantly lower in medium-dose group compared to other groups (p < 0.05). Incidence of adverse reactions were significantly lower in low and medium-dose groups compared to high- dose group (p < 0.05).
 Conclusion: Medium-dose dexmedetomidine demonstrates favorable sedative and analgesic effects with minimal impact on cognitive function and stress response in elderly patients undergoing lower limb surgery. Furthermore, it does not affect quality of postoperative recovery nor incidence of postoperative delirium. More large-scale, randomized controlled studies are needed to confirm these results.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"90 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135685465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：